{"schema_version":"1","generated_at":"2026-11-14T00:10:29.588Z","data_as_of":null,"url":"https://www.findmykol.com/kol/joshua-donaldson","json_url":"https://www.findmykol.com/kol/joshua-donaldson/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"joshua-donaldson","name":"Joshua Donaldson","credential":"MD, PhD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Nashville","state":"TN","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1508122151","orcid":"0000-0003-3879-833X","openalex":"A5029791073"},"summary":"Joshua Donaldson is an Oncology physician. OpenAlex indexes 21 publications with 599 citations (h-index 11).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":21,"cited_by_count":599,"h_index":11,"latest_activity_year":2023,"source":"works"},"prescribing":{"data_year":2023,"areas_total":1,"areas_shown":1,"areas":[{"area":"Cancer & immunology","share_pct":100,"classes_total":1,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":100,"drugs":[{"name":"Letrozole","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"mixed","data_year":2022,"office_pct":46,"facility_pct":54},"source":"medicare"},"publications":{"total":21,"shown":5,"withheld":16,"matched_by":"OpenAlex author record","recent":[{"title":"Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development","year":2023,"journal":"Cancer Discovery","source_url":"https://doi.org/10.1158/2159-8290.cd-23-1226","status":"verified"},{"title":"Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer","year":2022,"journal":"Cancer Research Communications","source_url":"https://doi.org/10.1158/2767-9764.crc-22-0023","status":"verified"},{"title":"NOTCH1 PEST domain variants are responsive to standard of care treatments despite distinct transformative properties in a breast cancer model","year":2022,"journal":"Oncotarget","source_url":"https://doi.org/10.18632/oncotarget.28200","status":"verified"},{"title":"Abstract P1-08-34: Peripheral immunity predicts therapeutic outcomes in breast cancer patients","year":2022,"journal":"Cancer Research","source_url":"https://doi.org/10.1158/1538-7445.sabcs21-p1-08-34","status":"verified"},{"title":"Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer","year":2021,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-19-4191","status":"verified"}],"source":"works"},"contact":{"address_1":"3601 THE VANDERBILT CLINIC","city":"Nashville","state":"TN","zip":"372324414","phone":"615-936-2000","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1508122151","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":16}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2022-03-31","provider_certified":"2022-03-31","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}